These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 8372725

  • 1. Toxicity of antimalarial drugs in rheumatoid arthritis.
    Rynes RI.
    Agents Actions Suppl; 1993; 44():151-7. PubMed ID: 8372725
    [Abstract] [Full Text] [Related]

  • 2. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH, Whelton A.
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [Abstract] [Full Text] [Related]

  • 3. The role of anti-malarials in rheumatoid arthritis--the American experience.
    Khraishi MM, Singh G.
    Lupus; 1996 Jun; 5 Suppl 1():S41-4. PubMed ID: 8803910
    [Abstract] [Full Text] [Related]

  • 4. More thoughts about antimalarials: should one prescribe chloroquine?
    Esdaile JM.
    J Rheumatol; 1999 Sep; 26(9):1868. PubMed ID: 10493663
    [No Abstract] [Full Text] [Related]

  • 5. Ophthalmologic monitoring for antimalarial toxicity.
    Sfikakis PP, Mavrikakis M.
    J Rheumatol; 2004 May; 31(5):1011-2; author reply 1012. PubMed ID: 15124272
    [No Abstract] [Full Text] [Related]

  • 6. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK, Furst DE.
    Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M, Akkasilpa S, Deesomchok U.
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [Abstract] [Full Text] [Related]

  • 11. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK, Furst DE.
    Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
    [Abstract] [Full Text] [Related]

  • 12. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE, Hong P, Koehler BE.
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Retinal toxicity due to antimalarials: frequency and risk factors.
    Palma Sánchez D, Rubio Velazquez E, Soro Marín S, Reyes García R.
    Reumatol Clin; 2013 Feb; 9(5):259-62. PubMed ID: 23707434
    [Abstract] [Full Text] [Related]

  • 18. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis.
    Aletaha D, Kapral T, Smolen JS.
    Ann Rheum Dis; 2003 May; 62(5):482-6. PubMed ID: 12695166
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM.
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.